Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$53.83 USD
-0.03 (-0.06%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $53.80 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PTGX 53.83 -0.03(-0.06%)
Will PTGX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains?
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Other News for PTGX
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Insider Sell: PATEL DINESH V PH D Sells Shares of Protagonist Therapeutics Inc (PTGX)
Protagonist Therapeutics Inc (PTGX) Submits NDA for Icotrokinra to FDA | PTGX stock news
Protagonist Therapeutics, Johnson & Johnson submit icotrokinra NDA to FDA
Protagonist announces NDA submission by Johnson & Johnson for icotrokinra